Lead Product(s) : Rodatristat Ethyl,Ambrisentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RVT-1201 (rodatristat ethyl) is a tryptophan hydroxylase inhibitor designed to reduce body’s peripheral production of serotonin, in preclinical study comparing rodatristat ethyl monotherapy and in combination with ambrisentan, in an animal model of PAH...
Product Name : RVT-1201
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2022
Lead Product(s) : Rodatristat Ethyl,Ambrisentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ELEVATE 2 will test the ability of rodatristat to reduce the peripheral production of serotonin through its unique mechanism of tryptophan hydroxylase (TPH) inhibition in order to improve PAH symptoms.
Product Name : RVT-1201
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2021
Lead Product(s) : Rodatristat Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rodatristat Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The studies demonstrated enhanced distribution of rodatristat ethyl in lung tissue consistent with levels associated with disease modification in preclinical models and also demonstrated minimal brain exposure supporting a lack of impact on brain seroton...
Product Name : RVT-1201
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2020
Lead Product(s) : Rodatristat Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable